Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer

BACKGROUND: Dexanabinol is a synthetic analogue of tetrahydrocannabinol identified as a potential anti-cancer therapeutic by e-Therapeutics PLC. Dexanabinol was selected for further investigation based on its preclinical tumoricidal activity. This phase I dose-escalation trial examined the safety, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Juarez, Tiffany M, Piccioni, David, Rose, Lara, Nguyen, Angel, Brown, Bradley, Kesari, Santosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883766/
https://www.ncbi.nlm.nih.gov/pubmed/33615223
http://dx.doi.org/10.1093/noajnl/vdab006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883766/
https://www.ncbi.nlm.nih.gov/pubmed/33615223
http://dx.doi.org/10.1093/noajnl/vdab006

Ejemplares similares